| Year |
Citation |
Score |
| 2021 |
Kong A, Mehanna H. WEE1 Inhibitor: Clinical Development. Current Oncology Reports. 23: 107. PMID 34269904 DOI: 10.1007/s11912-021-01098-8 |
0.35 |
|
| 2019 |
Mumin NH, Drobnitzky N, Patel A, Lourenco LM, Cahill FF, Jiang Y, Kong A, Ryan AJ. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. Bmc Cancer. 19: 102. PMID 30678647 DOI: 10.1186/s12885-019-5295-z |
0.586 |
|
| 2018 |
Garcia Foncillas J, Aftimos PG, Barthelemy P, Bellmunt J, Berchem G, Camps C, de Las Peñas R, Finzel A, Hervonen JP, Joensuu T, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, et al. Clinical utility of complex multi-platform profiling in metastatic cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii480. PMID 32137238 DOI: 10.1093/Annonc/Mdy294.004 |
0.348 |
|
| 2017 |
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168: 357-364. PMID 29198055 DOI: 10.1007/s10549-017-4596-7 |
0.497 |
|
| 2016 |
Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. Plos Biology. 14: e1002414. PMID 26949965 DOI: 10.1371/journal.pbio.1002414 |
0.697 |
|
| 2015 |
Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Medical Press). 7: 147-62. PMID 26089701 DOI: 10.2147/BCTT.S54414 |
0.768 |
|
| 2015 |
Leung WY, Roxanis I, Sheldon H, Buffa FM, Li JL, Harris AL, Kong A. Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget. 6: 5678-94. PMID 25691057 |
0.824 |
|
| 2015 |
Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets and Therapy. 7: 147-162. DOI: 10.2147/BCTT.S54414 |
0.768 |
|
| 2014 |
Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5: 5934-49. PMID 25153719 |
0.839 |
|
| 2014 |
Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, ... ... Kong A, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5: 6633-46. PMID 24952873 |
0.675 |
|
| 2014 |
Im S, Juric D, Baselga J, Kong A, Martin P, Lin C, Dees EC, Schellens JHM, De Braud FG, Delgado L, Zucchetto M, Tian X, Fernandez R, Morozov A, Dirix LY. A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer. Journal of Clinical Oncology. 32: 2519-2519. DOI: 10.1200/Jco.2014.32.15_Suppl.2519 |
0.434 |
|
| 2014 |
Albukhari A, Choudhry H, Haider S, Buffa F, Ahmed A, Kong A. 529: Identification of novel determinants of cetuximab-resistance in triple negative breast cancer European Journal of Cancer. 50: S128. DOI: 10.1016/S0959-8049(14)50471-6 |
0.776 |
|
| 2013 |
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, ... ... Kong A, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research : Bcr. 15: R92. PMID 24286369 DOI: 10.1186/Bcr3493 |
0.507 |
|
| 2013 |
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, ... ... Kong A, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 4: 1592-605. PMID 24009064 DOI: 10.18632/Oncotarget.1148 |
0.804 |
|
| 2013 |
Awada A, Rodriguez AA, Kong A, Erban JK, Cortes J, Mano MS, Perez EA, El Hariry I, Vukovic VM, Teofilovici F, Yalcin I, Bradley R, Cameron DA. The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 31: TPS1136-TPS1136. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps1136 |
0.557 |
|
| 2013 |
Awada A, Spector N, El-Hariry I, Rodriguez A, Erban J, Cortes J, Gomez H, Kong A, Hickish T, Fein L, Vahdat L, MacPherson I, Canon J, Mansoor S, Giovanne A, et al. Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-16-23 |
0.378 |
|
| 2012 |
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. Journal of the National Cancer Institute. 104: 1625-34. PMID 22962693 DOI: 10.1093/jnci/djs374 |
0.3 |
|
| 2012 |
Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 629-37. PMID 22410461 DOI: 10.2967/jnumed.111.096685 |
0.328 |
|
| 2012 |
Nafi SM, Kong A, Gijsen M, Kramer-Marek G, Capala J. 415 Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer European Journal of Cancer. 48: 126. DOI: 10.1016/S0959-8049(12)72213-X |
0.663 |
|
| 2012 |
Pistilli B, Urruticoechea A, Chan S, Han H, Jerusalem G, Kong A, Ru Q, Ruquet S, Sternberg D, Saura C. Ph Ib/Ii Study Of BKM120 Plus Trastuzumab (T) in Patients With T-resistant HER2+ Advanced Breast Cancer (BC) Annals of Oncology. 23: ix116. DOI: 10.1016/s0923-7534(20)32887-8 |
0.448 |
|
| 2012 |
Feldinger K, Kerry J, Gijsen M, Murphy G, Kong A. 86P The Role of Adam17 in Her2 Moderately Expressing Breast Cancer Annals of Oncology. 23: ii39. DOI: 10.1016/s0923-7534(19)65750-9 |
0.768 |
|
| 2012 |
Gijsen M, Tang P, Leung W, Roxanis I, Kong A. 24P PTPN9 is a Negative Regulator of HER3 Phosphorylation and a Prognostic Biomarker in HER2 Positive Breast Cancer Annals of Oncology. 23: ii21-ii22. DOI: 10.1016/s0923-7534(19)65669-3 |
0.643 |
|
| 2011 |
Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget. 2: 728-36. PMID 21908901 DOI: 10.18632/oncotarget.313 |
0.438 |
|
| 2011 |
Waterhouse BR, Gijsen M, Tullis I, Barber P, Vojnovic B, Kong A. Abstract 2235: FRET assay to assess EGFR/HER2 dimerization in cancer cell lines Cancer Research. 71: 2235-2235. DOI: 10.1158/1538-7445.Am2011-2235 |
0.42 |
|
| 2010 |
Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. Plos Biology. 8: e1000563. PMID 21203579 DOI: 10.1371/journal.pbio.1000563 |
0.728 |
|
| 2010 |
Gijsen M, King P, Perera T, Parker P, Larijani B, Harris A, Kong A. Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer Breast Cancer Research. 12. DOI: 10.1186/bcr2493 |
0.697 |
|
| 2008 |
Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. Plos One. 3: e2881. PMID 18682844 DOI: 10.1371/journal.pone.0002881 |
0.682 |
|
| 2008 |
Kong A, Calleja V, Leboucher P, Harris A, Parker P, Larijani B. Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells European Journal of Cancer Supplements. 6: 9. DOI: 10.1016/S1359-6349(08)71210-2 |
0.704 |
|
| 2006 |
Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, Parker PJ, Larijani B. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Research. 66: 2834-43. PMID 16510606 DOI: 10.1158/0008-5472.CAN-05-2994 |
0.747 |
|
| Show low-probability matches. |